Head-to-head · WeighScore
NewSelf vs Teleios Health
By GLP-1 ScorecardUpdated
Score comparison
NewSelf has the higher recorded score — 79.8/100 to 60.2/100.
NewSelf grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Round-$100 semaglutide, $144 tirzepatide, verified and available in all 50 states.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | NewSelf | Teleios Health |
|---|---|---|
| WeighScore | 79.8/100 | 60.2/100 |
| Grade | C+ | C |
| Site position | #39 | #372 |
| Semaglutide | $100/mo | $99/mo (starting dose, compounded) |
| Tirzepatide | $144/mo | $139/mo (starting dose, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #39 · C+
FDAWarning letter issued to NewSelf Limited dba NewSelf in February 2026. See the FDA warning-letter database.
Strengths
- $100 sema / $144 tirz
- All 50 states, LegitScript-verified
- Both molecules
What to consider
- Injection-only
- Labs/monitoring detail sparse
- Limited brand history
Site position #372 · C
Strengths
- Compounded semaglutide from $99/mo — among the lowest floor prices in cash-pay telehealth
- Compounded tirzepatide from a competitive $139/mo floor
- Markets physician (MD/DO) prescribing rather than an NP-only model
- Clean meta-tag and SEO implementation
What to consider
- Single-page app: state availability, pharmacy partner, dose pricing, lab requirements, and refund policy aren't visible and couldn't be verified
- No named medical director, physician, or corporate entity disclosed
- Year founded unknown — a newer floor-price entrant warranting extra scrutiny
- No LegitScript, NABP, or SOC 2 trust signal found
- Heavy paid-acquisition ad-tech stack — pair with diligence on the clinical layer
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.